MARKET

CDTX

CDTX

Cidara
NASDAQ

Real-time Quotes | Nasdaq Last Sale

3.977
+0.077
+1.96%
Opening 15:10 08/10 EDT
OPEN
3.950
PREV CLOSE
3.900
HIGH
4.000
LOW
3.831
VOLUME
61.47K
TURNOVER
--
52 WEEK HIGH
4.450
52 WEEK LOW
1.223
MARKET CAP
162.03M
P/E (TTM)
-3.4788
1D
5D
1M
3M
1Y
5Y

Analyst Rating

Based on 6 analysts

Strong Buy

Disclaimer: The analysis information is for reference only and does not constitute an investment recommendation.

Analyst Price Target

The average CDTX stock price target is 6.61 with a high estimate of 10.00 and a low estimate of 4.000.

EPS

CDTX News

More
Cidara Therapeutics to Present at the 2020 Wedbush PacGrow Healthcare Virtual Conference
SAN DIEGO, Aug. 04, 2020 (GLOBE NEWSWIRE) -- Cidara Therapeutics, Inc. (Nasdaq: CDTX), a biotechnology company developing long-acting therapeutics to transform the standard of care for patients facing serious fungal or viral infections, today announced that Je
GlobeNewswire · 6d ago
Cidara Therapeutics Announces Formation of Scientific Advisory Board
Comprised of World-Renowned Experts in Virology, Fungal Diseases and HematologySAN DIEGO, July 27, 2020 (GLOBE NEWSWIRE) -- Cidara Therapeutics, Inc. (Nasdaq: CDTX), a biotechnology company developing long-acting therapeutics to transform the standard of care
GlobeNewswire · 07/27 12:00
Cidara Therapeutics to Participate in B. Riley Virtual Summer Series Panel on Antiviral Therapeutics
SAN DIEGO, July 17, 2020 -- Cidara Therapeutics, Inc. (Nasdaq: CDTX), a biotechnology company developing long-acting therapeutics to transform the standard of care for patients.
GlobeNewswire · 07/17 12:00
Here is What Hedge Funds Think About Cidara Therapeutics Inc (CDTX)
Insider Monkey · 07/06 03:02
Russell adds lineup of healthcare firms to key indexes
Seeking Alpha - Article · 06/29 12:25
Cidara Therapeutics Added To Russell 3000 Index
Benzinga · 06/29 12:21
Cidara Therapeutics Added to Russell 3000® Index
Cidara Therapeutics, Inc. (CDTX), a biotechnology company developing long-acting therapeutics to transform the standard of care for patients facing serious fungal or viral infections, today announced that it has been added to the Russell 3000® Index at the con
GlobeNewswire · 06/29 12:00
Cidara Therapeutics to Participate in Cantor Fitzgerald Virtual Symposium: Winning Ways to Treat Infections and COVID-19
Cidara Therapeutics, Inc. (CDTX), a biotechnology company developing long-acting therapeutics to transform the standard of care for patients facing serious fungal or viral infections, today announced that Jeffrey Stein, Ph.D., President and Chief Executive Off
GlobeNewswire · 06/23 12:00

Industry

Biotechnology & Medical Research
+0.32%
Pharmaceuticals & Medical Research
+0.14%

Hot Stocks

Symbol
Price
%Change

About CDTX

Cidara Therapeutics Inc., is a clinical-stage biotechnology company focused on developing new anti-infectives. The Company’s lead product candidate is rezafungin acetate, which is a molecule in the echinocandin class of antifungals for the treatment and prevention of serious invasive fungal infections, including candidemia and invasive candidiasis, fungal infections associated with high mortality rates. The Company is also leveraging its novel Cloudbreak platform to develop antibody-drug conjugates for the treatment of serious viral and Gram-negative bacterial infections. Cloudbreak is the immunotherapy discovery platform designed specifically to create compounds that directly kill pathogens and also direct a patient’s immune cells to attack and eliminate bacterial, fungal or viral pathogens.
More

Webull offers kinds of Cidara Therapeutics Inc stock information, including NASDAQ:CDTX real-time market quotes, financial reports, professional analyst ratings, in-depth charts, corporate actions, CDTX stock news, and many more online research tools to help you make informed decisions.

You can practice and explore trading CDTX stock methods without spending real money on the virtual paper trading platform.